You can buy Tepodx at the lowest price at Nextgen.ooo online pharmacy. Tepotinib is a MET tyrosine kinase inhibitor intended for the treatment of a variety of solid tumors with overexpression of MET. It was originally developed in a partnership between EMD Serono and The University of Texas MD Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancer, non-small cell lung cancer, and hepatocellular carcinoma. MET is a desirable target in the treatment of certain solid tumors because it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is elevated and/or mutated. Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancer (NSCLC) with MET alterations, and then received accelerated approval from the US FDA in February 2021 under the brand name Tepmetko for the treatment of adult patients with metastatic NSCLC and MET exon 14 skipping alterations. It is the first oral tyrosine kinase inhibitor targeting MET that allows for once-daily dosing, which may help ease the pill burden often associated with chemotherapy regimens. Tepotinib was approved for use in Europe in February 2022.